Compare Capri Holdings Ltd (CPRI) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capri Holdings Ltd vs Charles River Laboratories Intl. Inc — how do they compare? Capri Holdings Ltd trades at $14.98 (market cap $1.67B), while Charles River Laboratories Intl. Inc trades at $302.17 (market cap $14.23B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 8.5× Capri Holdings Ltd's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Capri Holdings Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Capri Holdings Ltd for 41 Days and Charles River Laboratories Intl. Inc for 33 Days on average.
| CPRI | CRL | |
|---|---|---|
Market Cap | $1.67B | $14.23B |
Volume | 3,722,279 | 1,176,885 |
Sector | Consumer Cyclical | Health |
52-Week High | $27.66 | $310.77 |
52-Week Low | $12.71 | $149.93 |
Typical Hold Time | 41 Days | 33 Days |
Enterprise Value | $2.95B | $17.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPRI trades at $14.83, up 2.7% with bullish technical signals and recent earnings beats. The stock shows strong momentum with three consecutive quarterly EPS beats and positive analyst sentiment (44% buy ratings). However, fundamentals reveal challenges with declining revenue ($4.44B in 2025 vs $5.7B in 2022) and negative net income (-$1.18B), though profitability metrics show improvement potential with 62.7% gross margins.
The outlook balances attractive valuation (P/S 0.51) against turnaround execution risks. Upside exists if brand revitalization succeeds, but investors face headwinds from Michael Kors weakness and competitive pressures. The consensus price target of $20.57 suggests 39% potential upside if recovery gains traction in H2 2026 as management projects.
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
